Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
- 1
- 2
Novel Oral Anticoagulants for Acute Coronary Syndrome, Atrial Fibrillation, and Venous Thromboembolism in the EU5 | Physician & Payer Forum | EU5 | 2015
How Are Payer Policies and Physician Preferences Shaping the Prescribing Landscape? The European oral anticoagulation market has undergone a dramatic expansion in the treatment armamentarium in…
Venous Thromboembolism, Atrial Fibrillation, and Acute Coronary Syndrome (Novel Oral Anticoagulants in LATAM – Evolving Treatments ) | Physician & Payer Forum | Brazil and Mexico | 2014
The launch of novel oral anticoagulants (NOACs), such as Bayer/Janssen’s Xarelto, Bristol-Myers Squibb/Pfizer’s Eliquis/Elicuis, and Boehringer Ingelheim’s Pradaxa/Pradaxar, in Brazil and…
Venous Thromboembolism, Atrial Fibrillation, and Acute Coronary Syndrome (Novel Oral Anticoagulants – Evolving Treatments ) | Physician & Payer Forum | China | 2014
Warfarin has been the mainstay of anticoagulation therapy for the past several decades, but difficulties associated with its use and the clinical management of patients have prompted the…
Venous Thromboembolism (U.S. Uptake of the Novel Oral Anticoagulants in Venous Thromboembolism: Impact of Physicians and Payers on Prescribing?) | Physician & Payer Forum | US | 2014
Venous thromboembolism (VTE) is a potentially fatal cardiovascular condition characterized by the development of a thrombus in the vasculature. Treatment options for VTE have been largely limited…
- 1
- 2
